ページ3 - 最高の女性のがん検診医師 - トップ70名の医師

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

医師は30年以上の経験を持つ免疫学者であり、免疫学の最先端分野であるウイルス療法を専門としています。 <\/p>

リガ医科大学を卒業し、内科でのインターンシップを修了しました。 <\/p>

現在、Pauls Stradins Clinical University Hospitalの臨床免疫学センターの責任者を務めています。<\/p>

教育と上級トレーニング コース

• 1989年 - ヘブライ大学で高等医学教育を受ける;
• 1995年 - ハダッサ大学病院で内科および消化器科の研修を修了する。
• 2001年 - 2002年 - ニューヨークのシナイ医学部肝疾患部門でスコット・フリードマン教授とのインターンシップを行う。

現在、リファート・サファディ教授は肝疾患治療の分野で優れた専門家であり、体細胞移植センターの開発委員会のメンバーで、ハダッサ医療センター肝疾患ユニットの責任者です。教授は複数の国際肝研究協会のメンバーであり、専門分野で多くの論文を執筆しています。サファディ教授は、科学医学ジャーナル「Clinical Science」の編集委員会メンバーです。

リファート・サファディ氏は、多くの科学賞の受賞者です。特に彼は、mRNAを用いた肝線維化の免疫調節過程の研究でハダッサ賞を繰り返し受賞しています。同じ分野での業績により、教授はシャロン・ドンスキー賞およびイスラエル消化器病学と肝臓学協会の賞も受賞しました。

Education

Istanbul University Cerrahpaşa Faculty of Medicine, 2002
Istanbul Fatih Sultan Mehmet Training and Research Hospital, Internal Medicine, 2010
Istanbul University Oncology Institute (Çapa), Medical Oncology, 2015
Medipol University Faculty of Medicine, Phytotherapy Education, 2018
University of Health Sciences, Vocational School of Health, Molecular Oncology, PhD Program, PhD, 2023

Experience

University Hospital, Newark, New Jersey, USA, Observer (2003-2004)
Siirt State Hospital, Internal Medicine (2010-2011)
Siirt State Hospital, Medical Oncology (2015)
Bakırköy Dr. Sadi Konuk Training and Research Hospital, Medical Oncology (2015-2018)
Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Medical Oncology, (Professor Doctor) (2018-Present)
Forensic Medicine 3. Specialization Board, Medical Oncology, Full Member (2019-Present)
Liv Hospital, Ulus, Park-time, Medical Oncology (2020-2022)
Şişli Kolan International Hospital, Park-time, Medical Oncology (2022-2023)

Medical Intrests

• Gastrointestinal System Tumours (Esophagus - Stomach and Large Bowel Cancer)
• Hepatobiliary System Tumours (Liver-Biliary Tract and Pancreatic Cancer)
• Breast Cancer
• Lung Cancer
• Genitourinary Cancers
• Immunotherapies and Target Therapies
• Molecular Oncology
• Immunotherapies
• Target Treatments
•  

Awards

2010-YDUS (Subspecialty Examination) 14th place in Turkey
2014- Oncology Institute Days Best Poster Award
2015- Turkish Medical Oncology Society Board Exam Qualification
2015- ESMO (European Society for Medical Oncology) Board Exam Qualification

Marmara University Faculty of Medicine, Department of Radiation Oncology Specialization training: 2012 -2016

Marmara University Faculty of Medicine (English) Undergraduate: 2004-2011

Sixteen Numbered Shirvan School (Azerbaijan) High School: 1998 -2004

Education

İnönü Üniversitesi Tıp Fakültesi (ingilizce) 1995- 2002

Work Experience

Başbakanlık S.H.Ç.E.K. Genel Müdürlüğü Kurum Hekimliği (2003)

Erciyes Üniversitesi Tıp Fakültesi Genel Cerrahi Uzmanlığı 2011

Yüzüncü Yıl Üniversitesi Temel ve İleri Düzey Endoskopik Girişimler Eğitimi 2011

İstanbul Hastanesi /Van 2011

Özel Malatya Hastanesi / Malatya2012

Bilgi Tıp Merkezi Keçiören /Ankara 2013

Özel Koru Sincan Hastanesi Sincan/Ankara 2013

Baş Tibb Mərkəzi /Baku Clinic Azerbaycan/Bakü 2013

Yüksek İhtisas Üniversitesi Özel Koru Ankara Hastanesi 2019

Özel Ankara Koru Hastanesi /Ankara 2019

Medical Interests

laparoscopic obesity
Laparoscopic abdominal and inguinal hernia repairs (with the latest techniques)

Postpartum laparascopic diastasis recti (the formation of a protrusion in the upper middle abdomen due to the separation of the muscles in the abdominal tissue) and abdominal hernias above the navel and and gobekustunde both diastasis recti repair and abdominal hernia repair from the skin with laparascopic scola method for the first time in Turkey laparascopic stomach hernia and antireflu surgery).  

Laparoscopic gallbladder surgeries, including cleaning the bile duct with trans-cystic choledochal irrigation in patients with bile sludge and stones less than 5mm in the bile duct, performed in the same session

Laparoscopic gallbladder surgeries in pregnant women during the 2nd and 3rd trimesters, i.e., after 12 weeks of pregnancy

Laparoscopic Appendectomy in Pregnancy

Anal disorders, anal fissures, all types of internal and external hemorrhoid surgeries, anal fissure, and anal fistula surgeries

Thyroid surgeries and cancers, parathyroid surgeries and cancers

Breast diseases and breast cancer surgery

Oncological surgery; liver and gallbladder and bile duct surgeries, stomach cancer surgery, colon cancer surgery, and liver resections for metastatic liver tumors

Education

Cumhuriyet University Faculty of Medicine, 2004
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine Residency, 2010
Karadeniz Technical University Faculty of Medicine Medical Oncology Residency, 2015

Experience

MD Andeson Cancer Center, USA, 2008
Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
Moffit Cancer Center , USA 2022
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine, 2010
İdil State Hospital Internal Medicine Clinic, 2011
Karadeniz Technical Universityniversitesi Faculty of Medicine, Medical Oncology Clinic, 2015
Istanbul Göztepe Training and Research Hospital, Medical Oncology Clinic, 2018
Yeniyüzyıl University Gaziosmanpaşa Hospital, Medical Oncology Clinic, 2020
Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

Scientific Membership

Turkish Medical Association (TTB)
Turkish Society of Medical Oncology (TTOD)
European Society for Medical Oncology (ESMO)
American Society of Medical Oncology (ASCO)

Medical Intrests

• Breast Cancer
• Lung Cancer
• Colon Cancer
• Stomach Cancer
• Rectal Cancer
• Ovarian Cancer
• Liver Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Kidney Cancer
• Larynx Cancer - Cancer of the Larynx
• Thyroid Cancer
• Head and Neck Cancers
• Gynaecological Cancers
• Pancreatic Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Uterine Cancer
• Brain Cancers - Brain Tumours
• Soft Tissue Cancer - Sarcomas
• Prostate Cancer
• Bladder Cancer
• Bile Tract Cancer
• Testicular Cancer
• Cervical Cancer
• Mouth, Tongue, Lip Cancers
• Gastrointestinal System Cancers
• Bone Tumours
• Trachea and Bronchial Cancers
• Skin Cancers - Skin Cancers
• Skeletal System Tumours
• Gallbladder Cancer
• Mesothelioma

Education

• Doctor of Medicine: Necmettin Erbakan University Meram Faculty of Medicine, 1994
• Internal Medicine Residency: Atatürk University Faculty of Medicine, 2004
• Internal Medicine Residency: Kafkas University Faculty of Medicine, 2007
• Medical Oncology Subspecialty Residency: Selçuk University Faculty of Medicine, 2010
• Medical Oncology Subspecialty Training: Istanbul University Oncology Institute, 2013

Experience

• Dailiye Assistant: Atatürk University Faculty of Medicine, 2005
• Asst. Assoc. Prof. Dr.: Kafkas University, 2006-2007
• Assistant Prof.: Selcuk University - Medical Oncology, 2007-2010
• Assistant Prof.: Istanbul University Oncology Institute - Medical Oncology, 2012-2013
• Uzm. Dr.: Istanbul University Oncology Institute - Medical Oncology, 2013-2017
• Assoc. Prof. Dr.: Istanbul University Oncology Institute - Medical Oncology, 2017-2023
• Prof. Dr.: Istanbul University Oncology Institute - Medical Oncology, 2023-present

Scientific Memberships

•  
• Turkish Society of Medical Oncology
• European Society of Medical Oncology (ESMO)
• American Society of Clinical Oncology (ASCO)
• Turkish Internal Medicine Specialty Society

Awards

• 2018: "Best Researcher of the Year" award, Istanbul University Oncology Institute
• 2016: TUBITAK Incentive Award in the field of "Cancer Research"

この医師は、高度な技術を持つ腫瘍専門医であり、固形腫瘍、小児腫瘍、血液悪性腫瘍を含むさまざまな癌の治療を専門としています。彼女は、ウィップル手術などの保守的および外科的治療の両方に精通しています。<\/p>

彼女はLady Hardinge Medical CollegeでMBBSを取得し、Maulana Azad Medical Collegeで内科のMDを取得しました。その後、Tata Memorial HospitalでDM医療腫瘍学を追求し、そこでコンサルタントとしても勤務しました。<\/p>

彼女は国際的および国内の腫瘍学会に所属しており、肺、乳房、婦人科、泌尿生殖器の癌に関する専門知識を持ち、免疫療法とメトロノミック療法に特に関心を持っています。<\/p>

医師はムンバイのTata Memorial Hospitalで外科腫瘍学の訓練を受け、エディンバラのRoyal College of SurgeonsでMRCSを修了しました。2000年に実践を開始し、2007年にCurie Manavata Cancer Centreを設立しました。19年の経験を持ち、医師は50,000件以上の癌手術を行い、200以上の臨床試験に参加しました。医師は多くの国際的および国内の出版物を持つ著者です。乳房および胸部外科腫瘍学を専門とし、医師はMUHSでDNB Superspecialty Surgical OncologyおよびBreast Surgeryの教授です。<\/p>

Dr. Ahmer Arif Shaikh is an MDS (Oral & Maxillofacial Surgery) with 3 years of experience in Surgical Oncology, working at the HCG Manavata Cancer Centre - Nasik. His key takeaways include:

• Expertise in oral cancer, organ preservation and functional rehabilitation of oral cancer patients
• Interest in preventive oral hygiene & early diagnosis of oral cancers
• Proficient in performing major maxillofacial and head & neck surgeries
• Fellowship training in Head & Neck Surgical Oncology from HCG Manavata Cancer Centre, Nashik
• Researcher with many publications under his name

ニコ・ミヒック医師はケベック市のラヴァル大学で家庭医学の研修を受け、マギル大学とモントリオール大学の教育病院で15年間救急医療に携わりました。彼はいくつもの記事を発表し、様々な委員会に参加し、モントリオール大学で家庭医学の講師を務めました。
12年前から、ミヒック医師はスペインのマドリードに移住し、仕事をしています。現在、彼はプライベートクリニックで患者を診察し、サンパブロCEU医科大学で医学を教え、ESA（欧州宇宙機関）の医療顧問を務め、スペインでエールフランスおよびKLM航空の国内コンサルティング医師を務め、マドリード病院のエグゼクティブヘルスプログラムの責任者です。